Detalhe da pesquisa
1.
Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer.
Br J Cancer
; 130(6): 941-950, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38245661
2.
Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10.
Br J Cancer
; 128(2): 255-265, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36482193
3.
Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trial.
Gynecol Oncol
; 172: 121-129, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37030280
4.
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial.
Lancet Oncol
; 23(7): 919-930, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35690073
5.
Modifiable pre-treatment factors are associated with quality of life in women with gynaecological cancers at diagnosis and one year later: Results from the HORIZONS UK national cohort study.
Gynecol Oncol
; 165(3): 610-618, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35351333
6.
EPIK-O/ENGOT-OV61: alpelisib plus olaparib vs cytotoxic chemotherapy in high-grade serous ovarian cancer (phase III study).
Future Oncol
; 18(31): 3481-3492, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-36066851
7.
Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial.
Lancet Oncol
; 22(2): 277-288, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33357510
8.
Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis.
Cancer
; 127(14): 2432-2441, 2021 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33740262
9.
Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee.
Gynecol Oncol
; 161(2): 502-507, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33612336
10.
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.
Lancet Oncol
; 21(5): 699-709, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32305099
11.
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial.
Lancet
; 394(10214): 2084-2095, 2019 12 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31791688
12.
European Menopause and Andropause Society (EMAS) and International Gynecologic Cancer Society (IGCS) position statement on managing the menopause after gynecological cancer: focus on menopausal symptoms and osteoporosis.
Int J Gynecol Cancer
; 30(4): 428-433, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32046979
13.
Real world outcomes in platinum sensitive relapsed ovarian, fallopian tube, or peritoneal cancer treated in routine clinical practice in the United Kingdom prior to poly-ADP ribose polymerase inhibitors.
Int J Gynecol Cancer
; 30(7): 1026-1033, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32321768
14.
Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data.
Gynecol Oncol
; 154(2): 441-448, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31118141
15.
Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci.
Br J Cancer
; 116(4): 524-535, 2017 Feb 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-28103614
16.
Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk.
Genet Epidemiol
; 39(8): 689-97, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26399219
17.
Corrigendum to "Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data" Gynecol. Oncol. 154 (2019) 441-448.
Gynecol Oncol
; 161(1): 328-329, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33551198
18.
Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer.
Carcinogenesis
; 36(11): 1341-53, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26424751
19.
Corrigendum to "Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data" [Gynecol. Oncol. 154 (2019) 441-448].
Gynecol Oncol
; 157(2): 558-559, 2020 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-32087992
20.
European Network of Gynaecological Oncological Trial Groups' requirements for trials between academic groups and industry partners - a new Model D for drug and medical device development.
Int J Gynecol Cancer
; 30(6): 730-734, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32404377